Palo Alto Investors LP Invests $8.54 Million in Aclaris Therapeutics, Inc. $ACRS

Posted by Brenda Bartman on Aug 28th, 2026

Palo Alto Investors LP purchased a new position in shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS – Free Report) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 1,613,430 shares of the biotechnology company’s stock, valued at approximately $8,535,045. Aclaris Therapeutics makes up approximately 0.0% of Palo Alto Investors LP’s holdings, making the stock its 25th biggest holding. Palo Alto Investors LP owned approximately 1.15% of Aclaris Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently bought and sold shares of ACRS. BlackRock Inc. bought a new position in shares of Aclaris Therapeutics during the second quarter worth $53,096,000. Rock Springs Capital Management LP grew its stake in shares of Aclaris Therapeutics by 0.4% during the first quarter. Rock Springs Capital Management LP now owns 4,472,650 shares of the biotechnology company’s stock valued at $16,772,000 after buying an additional 18,909 shares during the last quarter. Millennium Management LLC raised its position in shares of Aclaris Therapeutics by 111.0% in the 1st quarter. Millennium Management LLC now owns 4,134,148 shares of the biotechnology company’s stock worth $6,325,000 after purchasing an additional 2,175,101 shares during the last quarter. Geode Capital Management LLC raised its holdings in Aclaris Therapeutics by 108.4% during the second quarter. Geode Capital Management LLC now owns 2,464,779 shares of the biotechnology company’s stock valued at $3,501,000 after acquiring an additional 1,282,042 shares during the period. Finally, Kalehua Capital Management LLC bought a new stake in shares of Aclaris Therapeutics during the first quarter worth $6,871,000. 98.34% of the stock is owned by institutional investors and hedge funds.

Aclaris Therapeutics Price Performance

ACRS traded down $0.15 during trading on Friday, hitting $6.01. The company had a trading volume of 1,220,839 shares, compared to its average volume of 1,929,825. The business has a 50-day moving average of $5.62 and a 200-day moving average of $4.57. The company has a market cap of $840.32 million, a PE ratio of -10.36 and a beta of 0.78. Aclaris Therapeutics, Inc. has a 1-year low of $1.74 and a 1-year high of $6.60.

Aclaris Therapeutics (NASDAQ:ACRS – Get Free Report) last issued its earnings results on Thursday, August 6th. The biotechnology company reported ($0.15) earnings per share for the quarter, beating the consensus estimate of ($0.16) by $0.01. Aclaris Therapeutics had a negative net margin of 921.50% and a negative return on equity of 61.65%. The business had revenue of $1.63 million for the quarter, compared to analyst estimates of $1.38 million. Research analysts forecast that Aclaris Therapeutics, Inc. will post -0.65 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on the stock. Guggenheim assumed coverage on shares of Aclaris Therapeutics in a report on Tuesday, May 5th. They issued a “buy” rating and a $12.00 price objective for the company. Lifesci Capital assumed coverage on Aclaris Therapeutics in a report on Tuesday, June 2nd. They set an “outperform” rating and a $13.00 price objective on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Aclaris Therapeutics in a research report on Wednesday, June 24th. Piper Sandler increased their price target on Aclaris Therapeutics from $7.00 to $11.00 and gave the stock an “overweight” rating in a report on Tuesday, May 5th. Finally, Wall Street Zen upgraded Aclaris Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, May 16th. Three research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $11.50.

Read Our Latest Stock Report on Aclaris Therapeutics

About Aclaris Therapeutics

(Free Report)

Aclaris Therapeutics, Inc (NASDAQ:ACRS) is a clinical‐stage biopharmaceutical company focused on discovering, developing and commercializing novel small‐molecule therapies for dermatologic diseases and related rare disorders. The company’s pipeline includes several product candidates designed to address chronic inflammatory skin conditions and non‐melanoma skin lesions. Lead programs include ATI‐50002, a topical agent in late‐stage development for molluscum contagiosum removal; ATI‐50003 for common wart resolution; ATI‐1501, an oral JAK1/2 inhibitor targeting pruritic disorders; and ATI‐450, an oral MK2 inhibitor for inflammatory indications.

Founded in 2016 and headquartered in Malvern, Pennsylvania, Aclaris leverages proprietary chemistry platforms and translational research capabilities to advance multiple clinical and preclinical candidates.